Abiomed Inc.
Impella Heart Pumps Demonstrate Survival Benefit in High-Risk PCI and Cardiogenic Shock Patients
Recent novel data presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2024 conference highlighted the safety and survival benefits of Abiomed's Impella heart pump technology in high-risk percutaneous coronary intervention (PCI) and cardiogenic shock patients. The data, which include results from a randomized controlled trial (RCT) published in the